Merck KGaA Announces Job Cuts
Merck KGaA has revealed further details about its previously announced restructuring program, including plans to eliminate approximately 580 jobs.
Merck KGaA has revealed further details about its previously announced restructuring program, including plans to eliminate approximately 580 jobs. A further 750 positions will be transferred from Switzerland to alternative sites primarily in Germany, the US, and China.
The company will close its Merck Serono headquarters in Geneva, Switzerland, and consolidate all headquarters functions in one site in Darmstadt, Germany. Of the current 1250 current positions in Geneva, 500 will be cut to eliminate duplications and the remaining 750 positions will be transferred. The aim of the transfers is to leverage scientific expertise in the biotechnology hub of Boston, Massachusetts, and to ensure clinical development in all key growth areas.
Despite the Swiss closure, Merck added in its statement that it intends to maintain a manufacturing and marketing presence in Switzerland. Currently, the company operates three manufacturing sites in the country in Aubonne, Corsier-sur-Vevey, and Coinsins. As part of the restructuring, operations in Coinsins will be transferred to the Aubonne site, and 80 jobs across all three sites will be eliminated. Out of the 750 jobs that will be transferred, more than 130 positions related to technical manufacturing in Geneva will be moved to Aubonne. The company also intends to maintain its Swiss market operations in Zug.
“The planned measures for Merck Serono’s operations in Switzerland are needed to ensure our global competitive position in a rapidly changing market and to secure the long-term future of the company,” Stefan Oschmann, executive board member of Merck and responsible for the Merck Serono division, explained in a statement.
Merck first announced the restructuring plan, and warned of upcoming workforce reductions, earlier in 2012.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
